Aravive (NASDAQ:ARAV) Rating Lowered to Hold at ValuEngine

Aravive (NASDAQ:ARAV) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a note issued to investors on Thursday, ValuEngine reports.

A number of other brokerages have also issued reports on ARAV. Wedbush began coverage on shares of Aravive in a research note on Monday, April 8th. They set an “outperform” rating and a $14.00 target price for the company. Zacks Investment Research lowered shares of Aravive from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. Finally, Piper Jaffray Companies began coverage on shares of Aravive in a research note on Monday, May 13th. They set an “overweight” rating and a $10.00 target price for the company.

Shares of NASDAQ:ARAV traded down $0.04 during trading on Thursday, reaching $6.56. 23,979 shares of the company traded hands, compared to its average volume of 23,755. The company has a fifty day simple moving average of $5.81. Aravive has a 1-year low of $3.07 and a 1-year high of $12.00. The company has a quick ratio of 7.78, a current ratio of 7.78 and a debt-to-equity ratio of 0.17.

Aravive (NASDAQ:ARAV) last issued its earnings results on Wednesday, May 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.44. The company had revenue of $1.70 million for the quarter. Equities research analysts expect that Aravive will post -2.19 earnings per share for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in ARAV. Northern Trust Corp bought a new position in shares of Aravive during the 4th quarter valued at $54,000. California Public Employees Retirement System bought a new position in Aravive in the 4th quarter worth $57,000. D. E. Shaw & Co. Inc. bought a new position in Aravive in the 4th quarter worth $73,000. Deutsche Bank AG bought a new position in Aravive in the 4th quarter worth $78,000. Finally, Millennium Management LLC bought a new position in Aravive in the 4th quarter worth $86,000. Institutional investors and hedge funds own 27.57% of the company’s stock.

About Aravive

Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.

See Also: How to trade on quiet period expirations

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.